(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide
(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxamide
CAS: 1006376-62-0
Molecular Formula: C10H9F2NO
(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide - Names and Identifiers
(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide - Physico-chemical Properties
| Molecular Formula | C10H9F2NO |
| Molar Mass | 197.18 |
| Density | 1.366±0.06 g/cm3(Predicted) |
| Melting Point | 145 - 147°C |
| Boling Point | 347.9±42.0 °C(Predicted) |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | 16.43±0.40(Predicted) |
| Storage Condition | 2-8°C |
| MDL | MFCD22380631 |
(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide - Reference Information
| ticagrelor | ticagrelor (ticagrelor) is an oral antiplatelet drug with the American brand name Brilinta and the European brand name Brilique. ticagrelor is a reversible platelet adenosine diphosphate (ADP) receptor antagonist designed to prevent platelets from sticking together and avoid the formation of blood clots that can lead to heart attacks and strokes. In the United States, ticagrelor was first approved by FDA in July 2011 for the treatment of adult patients with acute coronary syndrome (ACS). Clinical data show that ticagrelor is significantly better than clopidogrel (clopidogrel) in reducing cardiovascular death within at least 12 months after ACS events. In addition, ticagrelor also reduces the incidence of stent thrombosis (ST) in the patient population who has received stent therapy for ACS. in June 2020, aslika (AstraZeneca) announced that the us food and drug administration (FDA) has approved anticoagulant Brilinta (ticagrelor) for patients with high-risk coronary artery disease (CAD) to reduce the risk of first heart attack or stroke. In November 2020, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved anticoagulant Brilinta(ticagrelor, ticagrelor) as a new indication, combined with aspirin, for the treatment of patients with acute ischemic stroke or high-risk transient ischemic attack (TIA), to reduce the risk of subsequent stroke. |
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: Ticagrelor Impurity 103 Visit Supplier Webpage Request for quotationCAS: 1006376-62-0
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxamide Visit Supplier Webpage Request for quotation
CAS: 1006376-62-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1006376-62-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Ticagrelor Impurity 103 Visit Supplier Webpage Request for quotationCAS: 1006376-62-0
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxamide Visit Supplier Webpage Request for quotation
CAS: 1006376-62-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1006376-62-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History